Duloxetine: A balanced and selective norepinephrine- and serotonin-reuptake inhibitor

American Journal of Health-System Pharmacy

Volumn 62, Issue 23, 2005, Pages 2481-2490

  Westanmo, Anders D ^a   Gayken, Jon ^b   Haight, Robert ^c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Antidepressants; Costs; Depression; Diabetic neuropathies; Dosage; Drug administration; Drug interactions; Duloxetine; Mechanism of action; Pharmacokinetics; Toxicity; Urinary incontinence

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; NORFLUOXETINE; PAROXETINE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ANOREXIA; AREA UNDER THE CURVE; ASTHENIA; AUTONOMIC DYSFUNCTION; CLINICAL TRIAL; COMA; CONSTIPATION; CREATININE CLEARANCE; DELIRIUM; DIABETIC NEUROPATHY; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; HYPERTHERMIA; INSOMNIA; LIBIDO DISORDER; LIVER DYSFUNCTION; MAJOR DEPRESSION; MENTAL DISEASE; MYOCLONUS; NAUSEA; ORGASM DISORDER; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REMISSION; REVIEW; RIGIDITY; SIDE EFFECT; SOMNOLENCE; STRESS INCONTINENCE; SWEAT GLAND DISEASE; TREATMENT OUTCOME; UNITED STATES; XEROSTOMIA;

EID: 28344442596     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050006     Document Type: Review

References (95)

1. Project on the Decade of the Brain. www.loc.gov/loc/brain/ (accessed 2004 Nov 20).
2. Blier P. Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response. J Psychiatry Neurosci. 2001; 26:S3-10.
3. Murray CJ, Lopez AD, eds. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard Univ. Press; 1996.
4. Greden JF. The burden of disease for treatment resistant depression. J Clin Psychiatry. 2001; 62(S22):5-9.
5. MacGillivray S, Arroll B, Hatcher S et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ. 2003; 326:1014.
6. Corey-Lisle PK, Nash R, Stang P et al. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med. 2004; 164:1197-204.
7. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry. 2001; 62(suppl 22):5-9.
8. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety. 1997; 6:10-8.
9. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord. 1990; 18:289-99.
10. Nelson JC. Synergistic benefits of serotonin and noradrenaline reuptake inhibition. Depress Anxiety. 1998; 7(suppl 1):5-6.
11. Nelson JC, Mazure CM, Zbowers MB Jr et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991; 48:303-7.
12. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol. 1994; 8:238-49.
13. Wheatley DP, van Moffaert M, Timmerman L et al. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe depressive disorder. J Clin Psychiatry. 1998; 59:306-12
14. Feighner JP, Cohn JB, Fahre LF Jr et al. A study comparing paroxetine, placebo, and imipramine in depressed patients. J Affect Disord. 1993; 28:71-9.
15. Danish University Antidepressant Group. Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord. 1993; 28(2):105-16.
16. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology. 1986; 90:131-8.
17. Wong DT, Bymaster FP, Mayle DA et al. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology. 1993; 8:23-33.
18. Melville JL, Katon W, Delaney K et al. Urinary incontinence in US women: a population based study. Arch Intern Med. 2005; 165:537-42.
19. Von Korff M, Dworkin SF, LeResche L et al. An epidemiologic comparison of pain complaints. Pain. 1998; 32:173-83.
20. Dworkin SF, Gitlin MJ. Clinical aspects of depression in chronic pain patients. Clin J Pain. 1991; 7:79-94.
21. Fishbain DA, Cutler R, Rosomoff HL et al. Chronic pain-associated depression: antecedent or consequence of chronic pain? A review. Clin J Pain. 1997; 13:116-37.
22. Baldessarini RJ. Drugs and the treatment of psychiatric disorders, depression, and anxiety disorders. In: Hardman JG1 Limbird LE, eds. Goodman and Gillman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001:447-83.
23. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001; 25:871-80.
24. Bymaster FP, Beedle EE, Findlay J et al. Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett. 2003; 13:4477-80.
25. Eli Lilly and Co. Cymbalta (duloxetine) product information, http://pi.lilly.com/us/cymbalta-pi.pdf (accessed 2004 Nov 30).
26. Goodwin GM. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J Clin Psychiatry. 1996; 57(S4):9-13.
27. Bailey JE, Potokar J, Coupoland N et al. The 5-HT3 antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin reuptake inhibitor in man. J Psychopharmacol. 1995; 9:137-41.
28. Brunello N, Mendlewicz J, Kasper S et al. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol. 2002; 12:461-75.
29. Christman AK, Fermo JD, Markowitz JS. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy. 2004; 24:1020-36.
30. Spruce MC, Potter J, Coppini DV. The pathogenesis and management of painful diabetic neuropathy: a review. Diabet Med. 2003; 20:88-98.
31. Sullivan MP, Yalla SV. Physiology of female micturition. Urol Clin N Am. 2002; 29:499-514.
32. Thor KB. Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence. Urology. 2003; 62(S4A):3-9.
33. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol. 2000; 40:161-7.
34. Skinner MH, Kuan HY, Pan A et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther. 2003; 73:170-7.
35. Lantz RJ, Gillespie TA, Rash TJ et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos. 2003; 31:1142-50.
36. Kuo F, Gillespie TA, Kulanthaivel P et al. Synthesis and biological activity of some known and putative duloxetine metabolites. Bioorg Med Chem Lett. 2004; 14:3481-6.
37. Kuo F, Gillespie TA, Kulanthaivel P et al. Corrigendum to "Synthesis and biological activity of some known and putative duloxetine metabolites." Bioorg Med Chem Lett. 2004; 14:3481.
38. Agency for Health Care Policy and Research. Clinical practice guideline number 5: depression in primary care, vol 2. Treatment of major depression. Rockville, MD: U.S. Department of Health and Human Services, 1993; AHCPR publication no. 93-0551.
39. American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000; 157(suppl 4):1-45.
40. Snow V, Lascher S, Mottur-Pilson C. Pharmacological treatment of acute major depression and dysthymia: clinical guideline, part 1. Ann Intern Med. 2000; 132:738-42.
41. Zimmerman M, Chelminski I, Posternak M. A review of the Hamilton Depression Rating Scale in healthy controls: implications for the definition of remission in treatment studies of depression. J Nerv Ment Dis. 2004; 192:595-601.
42. Judd LL, Akiskal HS, Maser JD et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998; 50:97-108.
43. Judd LL, Paulus MJ, Schettler PJ et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry. 2000; 157:1502-4.
44. Goldstein DJ, Mallinckrodt C, Lu Y et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry. 2002; 63:225-31.
45. Detke MJ, Lu Y, Goldstein DJ et al. Duloxetine 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002; 63:308-15.
46. Detke MJ, Lu Y, Goldstein DJ et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatric Res. 2002; 36:383-90.
47. Goldstein DJ, Lu Y, Detke MJ et al. Duloxetine in the treatment of depression: a double-blind, placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004; 24:389-99
48. Little RJ, Raghunathan T. On summary measures analysis of the linear mixed effects model for repeated measures when data are not missing completely at random. Stat Med. 1999; 18:2465-78.
49. Mallinckrodt CH, Raskin J, Wohlreich MM et al. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials. BMC Psychiatry. 2004; 4:26.
50. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001; 178:234-41.
51. Furukawa T, McGuire H, Barbui C. Low dosage tricyclic antidepressants for depression. Cochrane Database Syst Rev. 2003; 3:CD003197.
52. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2003. www.cdc.gov/diabetes/pubs/factsheet.htm (accessed 2005 Aug).
53. Benbow SJ, MacFarlane IA. Painful diabetic neuropathy. Baillieres Best Pract Res Clin Endocrinol Metab. 1999; 13:295-308.
54. Harris M, Eastman R, Cowic C. Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population. Diabetes Care. 1993; 16:1446-52.
55. Hansson PT, Dickenson AH. Pharmacological treatment of peripheral neuropathic conditions based on shared commonalities despite multiple etiologies. Pain. 2005; 113:251-4.
56. Mendell JR, Sahenk Z. Painful sensory neuropathy. N Engl J Med. 2003; 348:1243-55.
57. Bo K. Pelvic floor muscle training is effective in treatment of female stress urinary incontinence, but how does it work? Int Urogynecol J. 2004; 15(2):76-84.
58. Fischer-Rasmussen W. Treatment of stress urinary incontinence. Ann Med. 1990; 22:455-65.
59. Weiss BD. Selecting medications for the treatment of urinary incontinence. Am Fam Physician. 2005; 71:315-22.
60. Al-Badr A, Ross S, Soroka D et al. What is the available evidence for hormone replacement therapy in women with stress urinary incontinence? JOGC. 2003; 25:567-74.
61. Alhasso A, Glazener CM, Pickard R et al. Adrenergic drugs for urinary incontinence in adults. Cochrane Database Syst Rev. 2003; 2:CD001842.
62. Nygaard IE, Heit M. Stress urinary incontinence. Obstet Gynecol. 2004; 104:607-20.
63. Eli Lilly and Company. FDA issues approvable letter for duloxetine for stress urinary incontinence (SUI); Lilly expects regulatory update on Cymbalta later this year. 2003. News release.
64. Eli Lilly and Company. Lilly and Boehringer Ingelheim jointly announce the recision of U.S. FDA application for duloxetine for treatment of stress urinary incontinence. 2005. News release.
65. Millard RJ, Moore K, Rencken R et al. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int. 2004; 93:311-8.
66. Van Kerrebroeck P, Abrams P, Lange R et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG Int Obstet Gynaecol. 2004; 111:249-57.
67. Dmochowski RR, Miklos JR, Norton PA et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol. 2003; 170(4, pt. 1):1259-63.
68. Norton PA, Zinner NR, Yalcin I et al. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol. 2002; 187:40-8.
69. McCormack PL, Keating GM. Duloxetine in stress urinary incontinence. Drugs. 2004; 64:2567-73.
70. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998; 59:502-8.
71. Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry. 1995; 56:574-9.
72. McGahuey CA, Gelenberg AJ, Laukes CA et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000; 26:25-40.
73. Raskin J, Goldstein DJ, Mallinckrodt CH et al. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry. 2003; 64:1237-44.
74. Eisenberg P, Eli Lilly and Company. "Dear Health Care Professional" letter. 2005 Oct 5.
75. Teng CH, Alan P, Clark C et al. Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2004; 57:652-6.
76. Brynne N, Svanstrom C, Aberg-Wistedt A et al. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. Br J Clin Pharmacol. 1999; 48:553-63.
77. Vandel P. Antidepressant drugs in the elderly-role of the cytochrome P450 2D6. World J Biol Psychiatry. 2003; 4:74-8.
78. Quitkin FM, McGrath PJ, Stewart JW et al. Chronological milestones to guide drug change: when should clinicians switch antidepressants? Arch Gen Psychiatry. 1996; 53:785-92.
79. Nierenberg AA, McLean NE, Alpert JE et al. Early nonresponders to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry. 1995; 152:1500-3.
80. Dawson R, Lavori PW, Coryell WH et al. Course of treatment received by depressed patients. J Psychiatr Res. 1999; 33:233-42.
81. Hirschfeld RM, Keller MB, Panico S et al. National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997; 277:333-40.
82. Keller MB. The long-term treatment of depression. J Clin Psychiatry. 1999; 60 (suppl 17):41-5.
83. Eli Lilly and Company and Boehringer Ingelheim. Yentreme receives approval across the European Union for the treatment of stress urinary incontinence in women. 2004. News release.
84. Dmochowski RR, Miklos JR, Norton PA et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. Obstet Gynecol Surv. 2004; 59(3):192-4.
85. McKesson. Average wholesale prices. www.mckesson.com (accessed 2005 Aug).
86. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001; 178:234-41.
87. Milnacipran: tricyclics remain first-line antidepressants. Rev Prescr. 1997; 17:791-5.
88. Guelfi JD, Ansseau M, Corruble E et al. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacol. 1998; 13:121-8.
89. Tignol J, Pujol-Domenech J, Chartres JP et al. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Acta Psychiatr Scand. 1998; 97:157-65.
90. Kasper S, Pletan Y, Solles A et al. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol. 1996; 11(suppl 4):35-9.
91. Ansseau M, von Frenckell R, Mertens C et al. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Psychopharmacology. 1989; 98:163-8.
92. Leinonen E, Lepola U, Koponen H et al. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression, Acta Psychiatr Scand. 1997; 96:497-504.
93. American Urological Association Female Stress Urinary Incontinence Clinical Guidelines Panel. Report on the surgical management of female stress urinary incontinence, www.auanet.org/timssnet/products/guidelines/main_reports/ fsuimainrpt.pdf (accessed 2005 Aug).
94. Scientific Committee of the First International Consultation on Incontinence. Assessment and treatment of urinary incontinence. Lancet. 2000; 355:2153-8.
95. Dworkin RH, Backonja M, Rowbotham MC et al. Advances in neuropathic pain. Diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003; 60:1524-34.